Department of Pathology and Molecular Pathology, University Hospital Zürich, University of Zürich, Switzerland.
Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI, Switzerland.
J Nucl Med. 2019 Sep;60(9):1270-1276. doi: 10.2967/jnumed.118.222307. Epub 2019 Feb 8.
The intense accumulation of prostate-specific membrane antigen (PSMA) radioligands in salivary glands is still not well understood. It is of concern for therapeutic applications of PSMA radioligands, because therapeutic radiation will damage these glands. A better understanding of the uptake mechanism is, therefore, crucial to find solutions to reduce toxicity. The aim of this study was to investigate whether the accumulation of PSMA-targeting radioligands in submandibular glands (SMGs) can be explained with PSMA expression levels using autoradiography (ARG) and immunohistochemistry (IHC). All patients gave written informed consent for further utility of the biologic material. The SMG of 9 patients, pancreatic tissue of 4 patients, and prostate cancer (PCA) lesions of 9 patients were analyzed. Tissue specimens were analyzed by means of PSMA-IHC (using an anti-PSMA-antibody and an immunoreactivity score system [IRS]) and ARG using Lu-PSMA-617 (with quantification of the relative signal intensity compared with a PSMA-positive standard). The SUV in salivary glands, pancreas, and PCA tissues were quantified in 60 clinical Ga-PSMA-11 PET scans for recurrent disease as well as the 9 primary tumors selected for ARG and IHC. PCA tissue samples revealed a wide range of PSMA staining intensity on IHC (IRS = 70-300) as well as in ARG (1.3%-22% of standard). This variability on PCA tissue could also be observed in Ga-PSMA-11 PET (SUV, 4.4-16) with a significant correlation between ARG and SUV ( < 0.001, = 0.897). On IHC, ARG, and Ga-PSMA-11 PET, the pancreatic tissue was negative (IRS = 0, ARG = 0.1% ± 0.05%, SUV of 3.1 ± 1.1). The SMG tissue displayed only focal expression of PSMA limited to the intercalated ducts on IHC (IRS = 10-15) and a minimal signal on ARG (1.3% ± 0.9%). In contrast, all SMG showed a high Ga-PSMA-11 accumulation on PET scans (SUV 23.5 ± 5.2). Our results indicate that the high accumulation of PSMA radioligands in salivary glands does not correspond to high PSMA expression levels determined using ARG and IHC. These findings provide evidence, that the significant accumulation of PSMA radioligands in SMG is not primarily a result of PSMA-mediated uptake.
前列腺特异性膜抗原(PSMA)放射性配体在唾液腺中的强烈积累仍然不太清楚。这是 PSMA 放射性配体治疗应用的关注点,因为治疗性辐射会损害这些腺体。因此,更好地了解摄取机制对于寻找减少毒性的解决方案至关重要。本研究旨在通过放射性自显影(ARG)和免疫组织化学(IHC)研究 PSMA 靶向放射性配体在颌下腺(SMG)中的积累是否可以用 PSMA 表达水平来解释。所有患者均书面同意进一步利用生物材料。分析了 9 名患者的颌下腺、4 名患者的胰腺组织和 9 名患者的前列腺癌(PCA)病变。通过 PSMA-IHC(使用抗 PSMA 抗体和免疫反应评分系统[IRS])和使用 Lu-PSMA-617 的 ARG(与 PSMA 阳性标准相比定量相对信号强度)分析组织标本。60 例 Ga-PSMA-11 PET 扫描用于复发性疾病的唾液腺、胰腺和 PCA 组织的 SUV 以及为 ARG 和 IHC 选择的 9 个原发性肿瘤的 SUV 进行了量化。PCA 组织样本的 IHC(IRS = 70-300)和 ARG(1.3%-22%的标准)显示 PSMA 染色强度范围广泛。在 Ga-PSMA-11 PET(SUV,4.4-16)中也可以观察到 PCA 组织中的这种变异性,ARG 和 SUV 之间存在显著相关性(<0.001,=0.897)。在 IHC、ARG 和 Ga-PSMA-11 PET 中,胰腺组织呈阴性(IRS = 0,ARG = 0.1%±0.05%,SUV 为 3.1±1.1)。SMG 组织仅在 IHC 上表现为局灶性 PSMA 表达,仅限于闰管(IRS = 10-15),ARG 上的信号最小(1.3%±0.9%)。相比之下,所有 SMG 在 PET 扫描中均表现出高 Ga-PSMA-11 积累(SUV 23.5±5.2)。我们的结果表明,唾液腺中 PSMA 放射性配体的高积累与使用 ARG 和 IHC 确定的 PSMA 高表达水平不对应。这些发现提供了证据,表明 SMG 中 PSMA 放射性配体的大量积累主要不是 PSMA 介导摄取的结果。